The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ: GILD )' Lenacapavir (LEN) for HIV ...

Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...

Based on the assessment of EMA’s Committee for Medicinal Products for Human Use (CHMP) that twice-yearly lenacapavir for prevention is a product of major interest for public health and ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Monday announced that the European Medicines Agency has validated its applications for accelerated review of lenacapavir, a twice-yearly injectable HIV-1 ...

Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...